Clicky

SKINBIO THERAP LS-01(5KW)

Description: SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.


Keywords: Infection Inflammation Psoriasis Microbiology Bacteriology Food Supplements Probiotic Digestive System Environmental Microbiology Croda International Microbiomes Human Microbiome University Of Manchester

Home Page: www.skinbiotherapeutics.com

The Core
Newcastle upon Tyne, NE4 5TF
United Kingdom
Phone: 44 19 1495 7325


Officers

Name Title
Mr. Stuart John Ashman CEO & Executive Director
Mr. Manprit Singh Randhawa CFO, Secretary & Director
Laura Bey Head of Formulations
Ms. Melissa Greenwell Group Financial Controller

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 11.7421
Price-to-Sales TTM: 290.2501
IPO Date:
Fiscal Year End: June
Full Time Employees: 11
Back to stocks